Compare Godaddy Inc (GDDY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Recursion Pharmaceuticals Inc — how do they compare? Godaddy Inc trades at $104.79 (market cap $13.07B), while Recursion Pharmaceuticals Inc trades at $4.27 (market cap $2.14B). The key difference: Godaddy Inc is far larger — about 6.1× Recursion Pharmaceuticals Inc's market cap, and Godaddy Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 65 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GDDY | RXRX | |
|---|---|---|
Market Cap | $13.07B | $2.14B |
Volume | 1,831,274 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $135.18 | $6.79 |
52-Week Low | $75.07 | $2.84 |
Typical Hold Time | 65 Days | 22 Days |
Enterprise Value | $15.75B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $104.7, up 7.7% in the last 24 hours, with a bullish technical signal from moving averages. The company reported revenue of $4.95B in 2025 and net income of $875M, with consistent earnings beats in recent quarters. However, the stock faces headwinds from a securities class action lawsuit alleging misrepresentations about domain contract terms, with a lead plaintiff deadline of October 20, 2026.
The outlook is mixed: strong profitability and earnings momentum support upside, but legal risks and a consensus price target of $96.20 suggest caution. Investors should weigh robust fundamentals against potential litigation impacts and market sentiment shifts.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
